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6 ABSTRACT: In the process of synthesis of a new drug, as important as the
7 drug itself is the formulation used, because the same compound can present a
8 very different efficacy depending on how it is administered. In this work, we
9 demonstrate how the antitumor capacity of a new octahedral organo-
10 ruthenium complex, [Ru(ppy-CHO)(phen)2][PF6] is affected by its
11 encapsulation in different types of mesoporous silica nanoparticles. The
12 interactions between the Ru complex and the silica matrix and how these
13 interactions are affected at two different pHs (7.4 and 5.4, mimicking
14 physiological and endolysosomal acidic conditions, respectively) have been
15 studied. The encapsulation has also been shown to affect the induction of
16 apoptosis and necrosis and progression of the cell cycle compared to the free
17 drug. The encapsulation of the Ru complex in nanoparticles functionalized
18 with amino groups produced very high anticancer activity in cancer cells in vitro, especially against U87 glioblastoma cells, favoring
19 cellular internalization and significantly increasing the anticancer capacity of the initial non-encapsulated Ru complex.
20 ■ INTRODUCTION
21 The global phenomenon of cancer is an ever-growing social
22 and economic burden and remains a major challenge in
23 modern medicine.1 Glioblastoma is one of the most aggressive
24 and highly invasive malignant tumors that accounts for
25 approximately half of adult brain tumors and is associated
26 with poor prognosis and overall short survival.2 A majority of
27 glioblastoma tumors are not amenable to surgery as these
28 neoplastic cells invade surrounding brain tissue, rendering
29 complete resection difficult.3 In addition, most cases of ovarian
30 epithelial carcinoma, which is a leading cause of cancer death
31 in women, are associated with poor prognosis and low survival
32 rates.4 Hence, there is an urgent need for novel chemo-
33 therapeutic formulations for these types of cancer.
34 The formulation of novel drugs using delivery systems is
35 essential to optimize their therapeutic performance. The way in
36 which a compound enters the body, reaches its place of action,
37 and interacts with the target tissues and cells can be modulated
38 by nanocarriers, which plays a key role in reaching the desired
39 effectiveness.5 By tuning the properties of the nanocarrier, the
40 delivery process can be adapted to the specific drug, which is
41 especially important when the compounds are insoluble or
42 cytotoxic, thus presenting a reduced activity or severe side
43 effects before reaching their target. Due to their unique and
44 versatile biochemical properties, ruthenium-based compounds
45 have emerged as very promising anticancer agents that can
46 serve as alternatives to cisplatin and its derivatives.6−10 For
47example, the ruthenium(III) complex NKP-1339 is undergoing
48clinical trials for cancer treatment,11 and RuII(η6-arene)
49complexes have been investigated for their tunability and
50novel modes of action.12−15 The combination of polypyridyl
51ruthenium drugs with nanoscale drug delivery systems has
52garnered a great deal of research attention.16,17 Compared with
53the planar structure of platinum drugs, the octahedral
54configuration of ruthenium complexes provides a rigid
55framework for the construction of a nanocarrier and their
56planar ligands may provide hydrophobic cavities for drug
57loading.18 However, many Ru complexes have limited capacity
58to cross the cell membrane.19,20
59Mesoporous silica nanoparticles (MSNs) have unique
60properties such as a large surface area, high stability and
61degree of tunability, and good biocompatibility, making them
62excellent vehicles for the delivery of any type of drug, especially
63one with antitumor purposes.21 Other materials widely used in
64drug delivery are liposomes and polymeric nanoparticles.
65Unlike the first ones with low stability or the second ones
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66 whose release kinetics are very fast, MSNs are resistant and
67 allow sustained release over time.22 Thus, MSNs are
68 potentially among the best nanocarriers for solving drug
69 delivery problems.21,23,24 Dysfunctional vascular architecture
70 represents a common feature of the tumor microenvironment
71 that presents a suitable situation for nanometric agents to pass
72 through efficiently because of the enhanced permeability and
73 retention (EPR) effect.25 Furthermore, the use of stimulus-
74 response nanoparticles favors drug release in a controlled
75 manner, following the accumulation in the tumor environment
76 and only after the desired stimulus. Said stimulus may come
77 from an external source (light, magnetic field, ultrasound, etc.)
78 or be defined by internal tumor conditions (redox, pH, etc.).26
79 The tumor microenvironment is known to be acidic due to
80 high cellular metabolic rates. This variation in pH has
81 previously been reported as strategy to uncap the silica
82 pores27,28 or to weaken drug−matrix interactions,29,30 in each
83 case triggering the release of the loaded molecules.
84 Despite that, so far only a few systems have combined MSNs
85 with Ru complexes, mainly for imaging applications.31,32
86 Frasconi et al. reported MSNs with kinetically inert ruthenium-
87 (II) polypyridyl complexes grafted on the surface,33 and Lv et
88 al. designed chitosan MSNs for the delivery of a ruthenium(II)
89 N-heterocyclic carbene (RuNHC) complex.34
90 However, to the best of our knowledge, no studies about
91 how different formulations affect the antitumor efficacy of a Ru
92 complex have been performed. In addition, it is necessary to
93 take into account how pH affects the different MSN−Ru
94 complex interactions when modifying the chemical nature of
95 the mesoporous matrix
96 Moreover, it has been recently shown that a class of
97 kinetically inert cyclometalated Ru(II) complexes of the type
98 [Ru(C^N)(N^N)2]
+ exhibits selective cytotoxicity in cancer
99 cells through a distinct mode of action that involves
100 proteosynthesis inhibition rather than targeting nuclear
101 macromolecules like DNA like other conventional metal-
102 based agents.35
103 Herein, we report our studies and comparison of the in vitro
104 anticancer activity of the octahedral cationic C,N-cyclo-
f1 105 metalated Ru(II) anticancer agent (Figure 1) [Ru(ppy-
106 CHO)(phen)2]
+ [ppy-CHO = deprotonated 4-(pyridin-2-
107 yl)benzaldehyde]
35 when administered free or loaded into
108 mesoporous silica nanoparticles. Special attention is also paid
109 to understand the consequences of using the nanoparticles as
110 drug transporters at the cellular level, its pH-dependent cargo
111 release and cancer cell internalization, and the mode of cell
112 death induced upon treatment.
113■ RESULTS AND DISCUSSION
114Preparation and Characterization of the Nano-
115systems. In this work, two different types of MSN have
116been synthesized: (i) bare ones, with silanol groups on the
117surface and negative ζ potentials, denoted as MSNs, and (ii) A-
118MSN, obtained by co-condensation between tetraethyl
119orthosilicate (TEOS) and (3-aminopropyl)triethoxysilane
120(APTES), which present amino groups and have positive ζ
121potentials. Scanning electron microscopy (SEM) images
122 f2(Figure 2) show that in both cases we have discrete particles
123of ∼200 nm for MSN and ∼150 nm for A-MSN. A complete
124characterization study shows that both nanoparticle types
125present similar pore arrangements and textural properties.
126The presence of amino groups was confirmed by Fourier
127transform infrared spectroscopy (FTIR). Figure S1A displays
128spectra of mesoporous silica nanoparticles with and without
129amine groups. The A-MSN sample shows the appearance of a
130new band at ∼1590 cm−1 corresponding to the bending
131vibration mode of N−H due to functionalization with -NH2
132groups. With regard to the structural characterization of MSN
133and A-MSN samples before ruthenium loading, powder X-ray
134diffraction (XRD) confirms the two-dimensional hexagonal
135mesoporous arrangement, displaying three well-defined
136reflections that can be indexed as 10, 11, and 20 of a p6mm
137space group for both materials. Additionally, the MSN shows
138an extra reflection index as 21 (Figure S1B).
139The porosities of MSN and A-MSN materials have been
140characterized by N2 adsorption/desorption analyses, and the
141main parameters are listed in Table S1. Panels C and D of
142Figure S1 show the N2 adsorption isotherms and mesopore
143size distributions, respectively. Isotherms are type IV according
144to the IUPAC classification, which are characteristic of
145mesoporous materials exhibiting parallel cylindrical pores.36
146Both the surface area (SBET) and the pore diameter (DP)
147decrease slightly when the amine groups are introduced by co-
148condensation compared to pure silica nanoparticles. These
149findings are in accordance with the calculated wall thickness
150(twall) values, which increase slightly when the walls are
151functionalized with amino groups. To acquire information
152regarding the mean size and surface charge of the nanosystems,
153dynamic light scattering (DLS) and ζ potential measurements
154were recorded. DLS measurements show good dispersions
155with a narrow size distribution in water for both types of
156nanoparticles (Figure S2). The mean hydrodynamic sizes
157determined by DLS were found to be 220 nm for MSN and
158180 nm for A-MSN, which, as expected, are slightly larger than
159those estimated from SEM images. ζ potential measurements
160recorded at two different pHs (7.4 and 5.4, mimicking
161physiological and endolysosomal acidic conditions, respec-
162tively) showed notable variations in the superficial charge of
163 t1the nanoparticles (Table 1). Ru complex loading was carried
164out by the impregnation method in a dimethylformamide
165(DMF) solvent, and the amount of drug loaded was calculated
166by subtracting the data obtained by thermogravimetric analysis
167(TG) for the loaded and unloaded samples. The percentage
168weight reduction includes evaporation of water (0−100 °C),
169degradation of most of he organic material (100−300 °C), and
170dehydration of the particle’s silanol groups starting at 300 °C.
171Therefore, only the difference in percentage weight reduction
172within the range of 100−300 °C (range in which the Ru
173complex is removed) was taken into account to calculate the
174amount of the loaded drug (Figure S3). The values obtained
Figure 1. Structure of the [Ru(ppy-CHO)(phen)2]
+ [C^N =
deprotonated 4-(pyridin-2-yl)benzaldehyde] complex.
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175 showed that both materials had a comparable loading capacity
176 with percentages of 1.47% and 2.12% (w/w) for MSN and A-
177 MSN, respectively.
178 The comparison of TEM images before and after loading for
f3 179 A-MSN, as an example (Figure 3), demonstrates that the
180 presence of the Ru complex inside the pores of the
181 nanoparticles does not modify the morphology of the
182 nanoparticles. Additionally, the presence of Ru was evaluated
183 using FTIR of the loaded samples (Figure S4) and energy
184 dispersive X-ray analysis (EDX). TEM−EDX and SEM−EDX
185 analysis (Figure S5) confirmed the presence of ruthenium
186 loaded inside the mesopores of nanoparticles. Ru was detected
187 by TEM−EDX analysis in the Ru@A-MSN sample but not in
188 Ru@MSN. The Ru@MSN sample loaded a smaller amount of
189 Ru compared to the amino-functionalized nanosystem, and
190 although the difference between both is very small, it coincides
191 with the detection limits of the TEM−EDX technique, which
192 makes it impossible to detect Ru in the Ru@MSN sample. On
193 the other hand, SEM−EDX analysis confirmed the presence of
194 Ru in both samples (Figure S5B).
195 “In Vial” Cargo Release Experiments. To ensure that
196 the integrity of the drug was not affected by the encapsulation
197process, the absorption spectrum of the complex was measured
198before loading and after being released by both types of
199nanoparticles. No differences were observed in any of the cases
200(Figure S6). Additionally, the stability of the complex after
201being released was also confirmed by mass spectrometry
202(Figures S7 and S8).
203Although the surface functionalization does not seem to
204significantly affect the morphological, structural, or textural
205properties of the particles, their important differences in ζ
206potentials (Table 1) have a considerable influence on the
207release profile of the complex.
208Ru release profiles for both Ru@MSN and Ru@A-MSN
209were obtained at two different pHs (7.4 and 5.4, mimicking
210physiological and endolysosomal acidic conditions, respec-
211tively). The Ru concentration after different assay times was
212quantified by absorption measurements (λ = 510 nm). As
213 f4shown in Figure 4, the release profile of Ru@A-MSN, with a ζ
214potential of 21.30 mV at pH 5.4, presents a very sharp initial
215burst and a release of practically 100% 72 h after the beginning
216of the experiment. This fast and extensive release is probably
217facilitated by repulsion forces between the positive charges of
218the Ru complex and the amino groups.
219In contrast, the profile of A-MSN at physiological pH, where
220the ζ potential is reduced to 9.37 mV and repulsion forces
221decrease, displays a slower and sustained release over time.
222MSN at pH 5.4 presents a ζ potential of −3.98 mV, closer to
223that of A-MSN at pH 7.4, which is consistent with the fact that
224they present similar release profiles. However, at pH 7.4, its ζ
225potential becomes more negative (−17.21 mV), favoring the
Figure 2. SEM images of (a) MSN and (b) A-MSN. Scale bars, 200 nm.
Table 1. ζ Potentials (millivolts) of MSN and A-MSN at
Two Different pHs
pH 5.4 pH 7.4
MSN −3.98 ± 0.36 −17.21 ± 0.74
A-MSN 21.30 ± 0.53 9.37 ± 0.39
Figure 3. TEM images of (a) A-MSN and (b) Ru@A-MSN.
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226 interactions with the Ru complex and therefore giving rise to a
227 minor release of approximately 10% of the loading 72 h after
228 the start of the experiment.
229 Release profiles can be adjusted to a first-order kinetic model
230 by introducing an empirical non-ideality factor (δ) to give the
231 following (eq 1):37
Y A(1 e )kt= − δ−232 (1)
233 where Y is the percentage of [Ru(ppy-CHO)(phen)2]
+
234 released at time t, A the maximum amount of Ru complex
235 released (in percentage), and k the release rate constant. The
236 values for δ are between 1 for materials that obey first-order
237 kinetics and 0 for materials that release the loaded cargo at the
238 very initial time of the test. The parameters of the kinetic
239 fitting shown in Figure S9 indicate that at pH 5.4 A-MSN
240 presents a kinetic of order of 0, releasing the cargo in a short
241 period of time probably due to the repulsion forces. The
242 obtained δ and k values for A-MSN at pH 7.4 and MSN at pH
243 5.4 are very similar, pointing to similar drug−matrix
244 interactions. Finally, the δ value for MSN at pH 7.4 is almost
245 1, pointing to a near first-order kinetics with a slight
246 contribution of an initial burst release of the loaded molecules.
247 In Vitro Biological Evaluation. Once both samples were
248 deeply characterized and their release response was tested “in
249 vial”, we proceeded to investigate their in vitro performance as
250 drug delivery nanocarriers.
251 The in vitro cytotoxicity of the drug-loaded nanoparticles
252 and their potential application in cancer treatment were
253 evaluated in cell culture models. The antiproliferative activities
254 of the nanoparticles were evaluated in U87 glioblastoma cells,
255 A2780 ovarian cancer cells, and CHO normal cells. After being
256 incubated for 2 h and cultured for 72 h, the nanoparticles
257showed cytotoxicity in a dose-dependent manner in all tested
258 f5cell lines (Figure 5).
259It is worth noting that both Ru@MSN and Ru@A-MSN
260proved to be markedly less cytotoxic to normal ovarian cells,
261suggesting differential selectivity toward cancer cells. Specifi-
262cally, Ru@A-MSN produced a reduction in cell viability 2
263times greater in U87 cells than in CHO cells for all
264concentrations and ≤4 times greater in A2780 cells for the
265maximum concentration. Compared to Ru@A-MSN, Ru@
266MSN did cause a smaller decrease in cell viability, indicating
267that the A-MSN nanocarrier might be suitable for use with
268small metal complexes with anticancer activity. Although Ru@
269A-MSN turned out to be more effective in both tumor cells, a
270more pronounced difference in cytotoxicity in U87 cells,
271coupled with the challenge of trying to treat a tumor as
272aggressive as glioblastoma, motivated the investigation to focus
273on this cell type.
274Therefore, a detailed cytotoxicity study of the loaded
275nanoparticles was carried out and compared with the effect
276caused by the empty nanoparticles and the equivalent amount
277of free Ru complex. U87 cells were incubated for 2 h with
278different concentrations (25, 50, and 100 μg/mL) of loaded or
279unloaded nanomaterials and analyzed 24 or 72 h later. Taking
280into account the loading capacity of Ru@A-MSN (2.12%), we
281added equivalent free Ru complex concentrations (approx-
282imately 0.5, 1, and 2 μg/mL, respectively) as a control. The
283 f6results in Figure 6 demonstrate that after 72 h, none of the
284unloaded nanoparticles were cytotoxic (viability of >90%) at
285concentrations of ≤100 μg/mL. Figure 6a shows that 24 h
286after the treatment, Ru@MSN did not produce significant
287death and free Ru reduced cell viability by only 10% at the
288maximum concentration tested. However, Ru@A-MSN
289managed to reduce cell viability by half at a Ru concentration
290of 1 μg/mL.
291Remarkably, an 8-fold concentration of free Ru was
292necessary to achieve the same effect (Figure S10). After 72
293h, Ru@MSN was able to reduce cell viability to 72%, and
294although in the presence of free Ru the viability was severely
295reduced to 31%, Ru@A-MSN was demonstrated to be the
296most effective treatment, reducing cellular viability to 15% in a
297dose-dependent manner. These results are consistent with the
298release profiles obtained for both types of particles. The
299maximum release of Ru@MSN up to 72 h is only around 20%
300of the total loading, which explains that at 24 h practically no
301cytotoxic effects are observed and after 72 h cell viability is just
302slightly reduced. In contrast, Ru@A-MSN had a large initial
303burst capable of producing a significant decrease in cell
304viability, and it eventually released almost 100% of the loading
305after 72 h, when most of the cancer cells have been killed.
Figure 4. “In vial” cumulative Ru complex release profiles for Ru@
MSN and Ru@A-MSN nanosystems at two different pHs (5.4 and
7.4).
Figure 5. Cytotoxicity of U87 glioblastoma cells, A2780 cancer cells, and CHO normal cells after treatment for 72 h with increasing concentrations
of Ru@MSN or Ru@A-MSN. The concentration is expressed as a function of the loaded Ru, and the blue dotted line indicates the control.
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306 The presence of amino groups on the surface of MSNs was
307 expected to improve the internalization of the cationic Ru
308 complex in cancer cells due to stronger interactions between
309 the positive A-MSN and the negatively charged phospholipids
310 of the cell membrane.38,39 To test that effect, U87 human
311 glioblastoma cells were incubated in the presence of size and ζ
312 potential value comparable fluorescein-labeled MSNs (see
313 Experimental Section for preparation and Figure S11 for
f7 314 characterization). As one can see in Figure 7, representative
315 confocal microscopy images revealed a larger amount of A-
316 MSN inside U87 tumor cells after incubation for 2 h as
317 compared to the amount of MSN, which showed negligible
318 internalization.
319 However, these differences in internalization seem to
320 decrease over time because when the incubation with the
321 loaded nanoparticles is carried out for a longer period of time
322 (24 h), the content of metal inside U87 cells, evaluated by
323 inductively coupled plasma mass spectrometry (ICP-MS),
324 showed that although the level of Ru was higher in cells treated
325 with Ru@A-MSN, Ru@MSN also led to important amounts of
326 Ru (Figure S12). What is more interesting is that treatment
327 with either type of nanoparticle resulted in a content of
328 ruthenium that was higher than that of the free equitoxic
329 complex. The results support the proposal of using nano-
330 particles for drug administration.
331 To better understand the effect of the encapsulation on
332 antitumor capacity, cell cycle progression studies and
333 apoptosis/necrosis induction studies were performed. The
334 progression of the cell cycle analysis shows that compared to
335 untreated U87 cells, treatment with Ru@A-MSN nanoparticles
336 produced cell death and increased the S phase cell population
337 slightly. However, Ru@MSN treatment resulted in an increase
338 in the G1 phase cell population with a concomitant reduction
339 in the S phase cell population. Moreover, treatment with an
340 equivalent quantity of the free ruthenium complex did not
f8 341 yield these minor cell cycle perturbations (Figure 8). In
342 contrast, the well-known DNA damage agent cisplatin slightly
343 induced S and G2/M phase arrest.40 Although these alterations
344 in cell cycle distribution were not significantly different from
345 untreated cells, the induced changes observed might be due to
346 the unique mechanism of action of the loaded Ru complex in
347 cancer, which involves the inhibition of proteosynthesis,33 a
348 process that occurs in the G1 phase.
349The cell death induction treatments in U87 were evaluated
350after 24 h using dual Annexin V/propidium iodide (PI)
351staining. The flow cytometric assay allowed the detection of
352necrotic cell populations (Annexin V−/PI+ quadrant) and
353both early and late apoptotic cells (Annexin V+ quadrants).
354Treatments with both Ru@MSN and Ru@A-MSN nano-
355particles revealed apoptotic induction as indicated by Annexin
Figure 6. Viability of U87 glioblastoma cells after treatment for 2 h with different concentrations of MSM, A-MSN, Ru@MSN, Ru@A-MSN, and
the equivalent free Ru complex and posterior culture for (a) 24 h or (b) 72 h, measured by Cell Counting Kit-8 (CCK-8). Statistical significance
was calculated using an unpaired t test. *p < 0.05 comparing loaded with unloaded nanoparticles. #p < 0.05 comparing Ru@A-MSN with the
equivalent free Ru complex. p < 0.05 comparing Ru@MSN with the equivalent free Ru complex.
Figure 7. Internalization study by confocal microscopy of 50 μg/mL
green-labeled nanopaticles after incubation for 2 h. The bottom and
side panels show the x−z and y−z cross-sectional images, respectively.
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356 V-labeled cell populations; Ru@A-MSN produced a greater
f9 357 extent of apoptosis (Figure 9). However, the administration of
358 the free ruthenium complex at equivalent concentrations in the
359 nanoparticles has not resulted in apoptotic cell death. This
360 clearly shows that delivery of the ruthenium complex using
361 these nanocarriers improved the promotion of cell death by
362 apoptosis in U87 cells.
363 ■ CONCLUSIONS
364 In this work, a new nanodrug based on [Ru(ppy-CHO)-
365 (phen)2][PF6]-loaded mesoporous silica nanoparticles has
366 been developed. The effects of the formulation on the
367 potential anticancer efficacy of the complex have been studied
368 in vitro against glioblastoma and ovarian cancer cells, with
369 particular focus on the interactions between the Ru complex
370 and the silica matrix at two different pHs (7.4 and 5.4,
371 mimicking physiological and endolysosomal acidic conditions,
372 respectively). Ru@A-MSN has demonstrated the highest
373 effectiveness against both tumor cell lines. For glioblastoma
374 cells, cell viability decreased to <50% after treatment for 24 h
375 for a concentration as low as 1 μg/mL, which is 8 times more
376 efficient than the free Ru complex. In addition, compared to
377 free equitoxic Ru complex treatment, administration of
378 nanocarriers resulted in a higher level of accumulation of
379 ruthenium within cancer cells; nanoparticles can slightly alter
380 the cell cycle progression in glioblastoma cells, particularly in
381the G1 phase, and cause moderate apoptotic cell death
382induction after 24 h.
383These outcomes demonstrate the importance of the
384formulation and nanosystems in the administration of a drug
385and open a new field of research that combines nanoparticles
386and Ru complexes for the treatment of cancer.
387■ EXPERIMENTAL SECTION
388Reagents. Tetraethylorthosilicate (TEOS, 98%), sodium hydrox-
389ide (NaOH, ≥98%), n-cetyltrimethylammonium bromide (CTAB,
390≥99%), ammonium nitrate (NH4NO3, ≥98%), (3-aminopropyl)-
391triethoxysilane (APTES, ≥98%), 4-(pyridin-2-yl)benzaldehyde
392(pyba), potassium hexafluorophosphate, fluorescein 5(6)-isothiocya-
393nate (FITC, ≥98%), and 1,10-phenanthroline (phen) were purchased
394from Sigma-Aldrich, and the ruthenium compound was purchased
395from Johnson Matthey. All chemicals were used as received without
396further purification.
397Characterization Techniques. XRD experiments were per-
398formed in a Philips X’Pert diffractometer equipped with Cu Kα
399radiation (wavelength of 1.5406 Å) (Philips Electronics NV,
400Eindhoven, The Netherlands). XRD patterns were collected in the
4012θ range of 0.6−8° with a step size of 0.02° and a counting time of 5 s
402per step. Thermogravimetric (TG) measurements were performed in
403a PerkinElmer Pyris Diamond TG/DTA instrument (heating from 25
404to 100 °C at 10 °C/min, hold for 5 min at 100 °C to remove all
Figure 8. Cell cycle analysis of U87 cells after treatment with Ru-
loaded nanoparticles (150 μg/mL) or equivalent free ruthenium
complex (3 μg/mL) for 3 h, determined by propidium iodide
intensity by flow cytometry.
Figure 9. Dual Annexin V-FITC (FL1-H)/propidium iodide (FL2-
H) flow cytometric analysis of U87 cells cultured for 24 h after
treatment (3 h) with loaded nanoparticles (150 μg/mL) or the
equivalent free ruthenium complex (3 μg/mL). Untreated cells were
used as a control. Statistical significance was calculated using an
unpaired t test (*p < 0.05) from two independent experiments (n = 2
replicates).
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405 remaining water, and heat from 100 to 900 °C). Fourier transform
406 infrared spectroscopy (FTIR) was carried out in a Nicolet (Thermo
407 Fisher Scientific, Waltham, MA) Nexus spectrometer equipped with a
408 Goldengate attenuated total reflectance (ATR) accessory (Thermo
409 Electron Scientific Instruments LLC, Madison, WI). The morphology,
410 mesostructural order, and nanoparticle functionalization were studied
411 by high-resolution transmission electron microscopy (HRTEM) with
412 a JEOL JEM 3000F instrument operating at 300 kV, equipped with a
413 CCD camera (JEOL Ltd., Tokyo, Japan). Sample preparation was
414 performed by dispersing in EtOH and subsequent deposition onto
415 carbon-coated copper grids. Energy dispersive X-ray analysis (EDX)
416 was carried out in combination with SEM and TEM. For this purpose,
417 TEM−EDX analyses were carried out with a JEOL JEM 1400 (JEOL
418 Ltd.) instrument equipped with a CCD camera (KeenView Camera)
419 and operated at 120 kV. SEM images were obtained with the Zeiss
420 Ultra Plus scanning electron microscope. Samples were prepared by
421 dispersion in ethanol and subsequent deposition onto a copper stud,
422 dried, and coated with a film of gold prior to observation. SEM−EDX
423 analysis was performed on a JEOL 6100 instrument operating at 20
424 kV. Samples were prepared by powder deposition onto a copper stud,
425 dried, and coated with a film of gold prior to observation.
426 To determine the surface charge of nanoparticles by ζ potential
427 measurements, a Zetasizer Nano ZS (Malvern Instruments) equipped
428 with a 633 nm “red” laser was used. ζ potential measurements were
429 recorded in aqueous colloidal suspensions at pH 5.4 and 7.4. For this
430 purpose, 1 mg of nanoparticles was added to 10 mL of solvent
431 followed by sonication for 5 min to obtain a homogeneous
432 suspension. In both cases, measurements were recorded by placing
433 1 mL of the suspension (0.1 mg mL−1) in DTS1070 disposable folded
434 capillary cells (Malvern Instruments). The textural properties of the
435 materials were determined by N2 adsorption porosimetry by using a
436 Micromeritics ASAP 2020 instrument (Micromeritics Co., Norcross,
437 GA). To perform the N2 measurements, 20−30 mg of each sample
438 was previously degassed under vacuum for 24 h at 40 °C. The surface
439 area (SBET) was determined using the Brunauer−Emmett−Teller
440 (BET) method, and the pore volume (VP) was estimated from the
441 amount of N2 adsorbed at a relative pressure of ∼0.97. The pore size
442 distribution between 0.5 and 40 nm was calculated from the
443 adsorption branch of the isotherm by means of the Barrett−
444 Joyner−Halenda (BJH) method. The mesopore size (DP) was
445 determined from the maximum of the pore size distribution curve.
446 C, H, and N analyses were performed with a Carlo Erba model EA
447 1108 microanalyzer. The 1H spectra were recorded on a Bruker AV
448 400 spectrometer. Chemical shifts are cited relative to the solvent
449 resonance. ESI mass (positive mode) analyses were performed on a
450 HPLC/MS TOF 6220 instrument.
451 Synthesis of Pure Silica (MSN) and Amino-Functionalized
452 (A-MSN) Mesoporous Silica Nanoparticles. Bare MSNs, denoted
453 as MSN, were synthesized by the modified Stöber method using
454 TEOS as the silica source in the presence of CTAB as the structure-
455 directing agent. Briefly, 1 g of CTAB, 480 mL of H2O, and 3.5 mL of
456 NaOH (2 M) were added to a 1 L round-bottom flask. The mixture
457 was heated to 80 °C and magnetically stirred at 600 rpm. When the
458 reaction mixture was stabilized at 80 °C, 5 mL of TEOS was added
459 dropwise at a rate of 0.33 mL min−1. The white suspension obtained
460 was stirred for a further 2 h at 80 °C. The nanoparticles were collected
461 by centrifugation, washed twice with water and twice with ethanol,
462 and stored in an ethanol suspension.
463 A-MSN was synthesized in the same way but replacing 10% of
464 TEOS with APTES.
465 Synthesis of Fluorescent Nanoparticles. For cellular internal-
466 ization studies, fluorescein-labeled MSNs were synthesized. For this
467 purpose, 1 mg of FITC and 2.2 μL of APTES were dissolved in 100
468 μL of ethanol and allowed to react for 2 h. Then the reaction mixture
469 was added with TEOS or with TEOS and APTES as previously
470 described.41
471 Synthesis of the Ru Complex (Ru). The ruthenium complex
472 [Ru(ppy-CHO)(phen)2][PF6] was prepared according to the
473 literature procedure reported by us.35
474Anal. Calcd for C36H24F6N5OPRu (788.66): C, 54.83; H, 3.07; N,
4758.88. Found: C, 54.72; H, 3.01; N, 8.93. ESI-MS (m/z): 644.1139 (M
476− PF6)+. 1H NMR (400 MHz, CD3CN, 25 °C): δ 9.59 (s, 1H), 8.50
477(dd, 1H, J = 8.21, 1.36 Hz), 8.40 (multiplet, 4H), 8.22 (dd, 1H, J =
4785.29, 1.20 Hz), 8.18 (d, 1H, J = 8.21 Hz), 8.16 (s, 2H), 8.12 (s, 2H),
4798.09 (dd, 1H, J = 4.97, 1.36 Hz), 8.05 (d, 1H, J = 8.06 Hz), 7.90 (dd,
4801H, J = 5.33, 1.20 Hz), 7.74 (td, 1H, J = 7.62, 1.54 Hz), 7.66 (dd, 1H,
481J = 5.66, 1.45 Hz), 7.63 (dd, 3H, J = 8.18, 5.21 Hz), 7.47 (dd, 1H, J =
4828.14, 5.33 Hz), 7.36 (dd, 1H, J = 7.98, 1.72 Hz), 6.93 (td, 1H, J =
4835.66, 1.45 Hz), 6.87 (d, 1H, J = 1.60 Hz).
484Loading with the Ru Complex. Two samples of 20 mg of MSN
485and A-MSN were collected by centrifugation and suspended in 2 mL
486of a DMF/Ru complex solution (3 mg/mL) while being stirred for 24
487h. Then, Ru@MSN and Ru@A-MSN samples were centrifuged and
488washed twice with water. After being washed, one sample of each type
489was dried under vacuum to carry out TG studies and the other was
490suspended in 800 μL of water for the release experiments.
491“In Vial” Cargo Release Assays. The suspensions of the previous
492section were divided into four vials each with a volume of 200 μL; 800
493μL of phosphate-buffered saline (PBS) with a pH 5.4 or 7.5 was used
494to obtain a final volume of 1 mL. The suspensions were sonicated for
495a few seconds, and then to avoid limitations of the delivery rate by
496external diffusion constraints, continuous stirring was maintained
497during the assays.
498After determined periods of time, samples were centrifuged, the
499PBS was collected, and a fresh 1 mL portion of the corresponding
500PBS was added to continue the release. The cumulative Ru complex
501released was determined by absorption measurements (λ = 510 nm).
502The Ru complex concentration was determined from the average of
503the readings from four different samples (N = 4), and data are
504presented as the mean ± the standard deviation. The calibration curve
505was made at both pHs ensuring that this parameter would not
506influence the results.
507Cell Culture. The U87 MG human glioblastoma cell line was
508cultured in Minimum Essential Medium Eagle (MEM) (Sigma-
509Aldrich) supplemented with 10% FBS and 1% L-glutamine. Human
510ovarian cancer cells (A2780) were cultured in Roswell Memorial Park
511Institute (RPMI)-1640 medium (Biowest ) supplemented with 10%
512FBS and 2 mM L-glutamine. Normal ovarian cancer cells, CHO
513(Chinese hamster ovary), were cultured in F-12 medium
514supplemented with 10% FBS and 2 mM L-glutamine. The cell lines
515were maintained in a humidified atmosphere of 5% CO2 at 37 °C with
516a subculture routine of two or three times per week at appropriate
517densities according to the cell line requirements.
518Internalization Assays in U87 MG Cells. Experiments were
519conducted in μ-Slide 8 Well ibiTreat #1.5 polymer coverslips (tissue
520culture-treated, sterilized). For nanoparticle uptake, cells were
521incubated with medium containing nanoparticle suspensions (50
522μg/mL) for 2 h. The chambers were thoroughly washed with PBS to
523remove the non-internalized particles. Then, cells were fixed with 4%
524paraformaldehyde for 20 min and washed twice with PBS. Then, cells
525were stained for 10 min by adding 200 μL of PBS and 1 μL of SYTO
52660 Red Fluorescent Nucleic Acid Stain (Molecular Probes) per well
527and washed with PBS. The images were acquired using a Leica SP8
528scanning confocal microscope (scanning confocal with lasers for 405,
529488, 552, and 638 nm and 3PMT detectors). For the purpose of
530presentation, pictures were exported in JPG format.
531Biocompatibility of MSN and A-MSN in U87 MG Cells. For
532the cell viability test, the cells were seeded on 24-well plates at an
533initial density of 25000 cells/well and left to attach for 24 h. The cells
534were treated with empty mesoporous silica nanoparticles at three
535different concentrations (25, 50, and 100 μg/mL). After the
536incubation period (24 or 72 h), cell viability was evaluated using
537Cell Counting Kit-8 (CCK-8) (Dojindo). The reagent was directly
538mixed with fresh medium and placed in contact with the cells for 1 h
539at 37 °C. Then, the absorbance at 450 nm was read. The viability was
540plotted as a percentage (%) of the absorbance normalized for the
541control.
542Cytotoxicity of the Free Ru Complex against U87 MG Cells.
543The cells were treated with increasing concentrations of the Ru
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544 complex and incubated for 2 h. Then, the cell viability was evaluated
545 (CCK-8). The reagent was directly mixed with fresh medium and
546 placed in contact with the cells for 1 h at 37 °C. Then, the absorbance
547 at 450 nm was read. The viability was plotted as a percentage (%) of
548 the absorbance normalized for the controls.
549 Cytotoxicity of Ru-Loaded Nanoparticles against U87 MG
550 Cells. The cells were treated with increasing concentrations of Ru-
551 loaded nanoparticles and incubated for 2 h. To remove the non-
552 internalized nanoparticles, the medium was removed and fresh
553 medium was added to the wells. Twenty-four or seventy-two hours
554 later, the cell viability was evaluated (CCK-8). The reagent was
555 directly mixed with fresh medium and placed in contact with the cells
556 for 1 h at 37 °C. Then, the absorbance at 450 nm was read. The
557 viability was plotted as a percentage (%) of the absorbance
558 normalized for the controls.
559 Cytotoxicity of Ru-Loaded Nanoparticles against A2780
560 and CHO Cells. Either tumoral (A2780) or nontumoral ovarian cells
561 (CHO) were seeded onto 96-well plates (5000 cells/well) and
562 incubated overnight at 37 °C in a humidified incubator with 5% CO2.
563 Cells treated with Ru@MSN or Ru@A-MSN were added at the
564 indicated concentrations for 72 h. Cell medium was removed by
565 suction, and 50 μL of Thiazolyl Blue Tetrazolium Bromide (MTT, 1
566 mg/mL) was added to the wells following a 4 h incubation under the
567 same experimental conditions. Then, the MTT solution was removed
568 and pure DMSO (50 μL) was used to solubilize the formazan crystal
569 formed in active cells. The absorbance was measured using a
570 FLUOstar Omega microplate reader at λ = 570 nm. The experiment
571 was perfomed in duplicate using six replicates. Data were analyzed
572 with SigmaPlot 14.0 and are represented as the mean ± the standard
573 deviation.
574 Determination of the Amount of Intracellular Ruthenium in
575 U87 Cells. The U87 cells were seeded in T 25 cm2 flasks at high
576 density and properly cultured until 70−80% confluence was achieved.
577 Cells were then treated with drug-loaded nanoparticles or the free
578 ruthenium complex at the indicated concentrations for 12, 24, or 48 h.
579 Cells were then trypsinized, collected, and counted using trypan blue
580 staining. After centrifugation, cell pellets were digested using 30%
581 Suprapur nitric acid for 24 h. The amount of metal element
582 ruthenium was determined using inductively coupled plasma mass
583 spectrometry (ICP-MS) in an Aligent Technologies system. Two
584 independent measurements for each replicate were taken.
585 Cell Cycle Progression Analysis. Cell cycle analysis in U87 cells
586 was evaluated by flow cytometry using propidium iodide staining.
587 Briefly, 80000 cells/well were seeded onto 12-well plates and
588 incubated overnight at 37 °C and 5% CO2. Nanoparticles or cisplatin
589 was added at the indicated concentrations for 24 h. Cells were then
590 collected by trypsinization and fixed in a 7:3 EtOH/PBS solution for 4
591 h. After fixation, cells were centrifuged, washed with PBS, and stained
592 with a propidium iodide (40 μg/mL) solution containing RNase (1
593 μg/mL) for 30 min. Cells were then subjected to flow cytometry
594 (Beckmann Coulter Epics XL) registering fluorescence at 620 nm in
595 the FL2-A channel. Two independent experiments were performed (n
596 = 2 replicates), and data analyzed using Flowing Software 2.5.1.
597 Apoptosis Induction Assay. The impact of nanoparticles on the
598 rate of apoptosis and necrosis in U87 cells was evaluated by flow
599 cytometry using dual Annexin V/propidium iodide staining. Briefly,
600 80000 cells/well were seeded onto 12-well plates and incubated
601 overnight at 37 °C in a humidified incubator with 5% CO2. Either
602 nanoparticles, the equitoxic free complex, or cisplatin was added at the
603 indicated concentrations for 24 h. Cells were then collected by
604 trypsinization, washed with binding buffer, and stained with an
605 Annexin V-FLUOS/propidium iodide solution (eBioscience) as
606 instructed by the manufacturer. Cells were then subjected to flow
607 cytometry (Beckmann Coulter Epics XL) registering fluorescence at
608 530 and 620 nm in FL1-H and FL2-H, respectively. Two independent
609 experiments were performed (n = 2 replicates), and data analyzed
610 using Flowing Software 2.5.1.
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625de Murcia, and Biomedical Research Institute of Murcia (IMIB-
626Arrixaca), E-30071 Murcia, Spain; orcid.org/0000-0002-
6270834-337X; Phone: +34 868887455; Email: jruiz@um.es
628Maria Vallet-Regí − Department of Chemistry in
629Pharmaceutical Sciences, School of Pharmacy, Universidad
630Complutense de Madrid, 28040 Madrid, Spain; Centro de
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646Universidad de Murcia, and Biomedical Research Institute of
647Murcia (IMIB-Arrixaca), E-30071 Murcia, Spain
648Luiza C. S. Erthal − School of Pharmacy and Pharmaceutical
649Sciences, Trinity College Dublin (TCD), Dublin 2, Ireland;
650Trinity Biomedical Sciences Institute, TCD, Dublin 2, Ireland
651Eduardo Ruiz-Hernandez − School of Pharmacy and
652Pharmaceutical Sciences, Trinity College Dublin (TCD), Dublin
6532, Ireland; Trinity Biomedical Sciences Institute, TCD, Dublin
6542, Ireland
655M. Dolores Santana − Departamento de Quiḿica Inorgańica,
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